Wednesday, March 09, 2011 3:58:55 PM
I wish to express my sincere appreciation towards you for the unselfish use of your valuable time and the stellar efforts you put forth in rebuffing the onslaught of unsubstantiated and repeated attempts by those few posters here who try to continuously discredit the science, and all those hard working professionals behind such an amazing and incredible discovery. Your knowledgeable depth in such matters keeps me well informed and reminds me as to why I am here, and as to why I have such a desire and high hope for this company to succeed. All this talk of high share price in order to gain wealth achievement must be placed in the proper peripheral sense, and that the real contribution here is not intended to satisfy the selfish, greedy lust for monetary reward, but rather to provide a necessary means to ease and eradicate from those places ravished with infliction and destitute with no means to help themselves. I for one am grateful towards all who place such a high priority on this this novel approach and the attempt to provide effective ways to treat those conditions of ailment that have none. My wish is that we all obtain our fulfillments of reward here for having endured the patients necessary to see this through, but without leveling undue conditions upon those who are obviously working diligently and aggressively to see their inner desires and dreams become reality as well.
Recent NNVC News
- NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/01/2023 08:46:45 PM
- Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs • InvestorsHub NewsWire • 07/06/2023 03:16:37 PM
FEATURED Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • May 17, 2024 11:00 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM
ILUS Provides a First Quarter Filing Update • ILUS • May 16, 2024 11:26 AM
Cannabix Technologies and Omega Laboratories Inc. enter Strategic Partnership to Commercialize Marijuana Breathalyzer Technology • BLO • May 16, 2024 8:13 AM
Avant Technologies to Revolutionize Data Center Management with Proprietary AI Software Platform • AVAI • May 16, 2024 8:00 AM